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Background: The microRNA 125b is a double-faced gene expression regulator described both as a tumor
suppressor gene (in solid tumors) and an oncogene (in hematologic malignancies). In human breast cancer, it is
one of the most down-regulated miRNAs and is able to modulate ERBB2/3 expression. Here, we investigated its
targets in breast cancer cell lines after miRNA-mimic transfection. We examined the interactions of the validated
targets with ERBB2 oncogene and the correlation of miR-125b expression with clinical variables.
Methods: MiR-125b possible targets were identified after transfecting a miRNA-mimic in MCF7 cell line and
analyzing gene expression modifications with Agilent microarrays and Sylamer bioinformatic tool. Erythropoietin
(EPO) and its receptor (EPOR) were validated as targets of miR-125b by luciferase assay and their expression was
assessed by RT-qPCR in 42 breast cancers and 13 normal samples. The molecular talk between EPOR and ERBB2
transcripts, through miR-125b, was explored transfecting MDA-MD-453 and MDA-MB-157 with ERBB2 RNA and
using RT-qPCR.
Results: We identified a panel of genes down-regulated after miR-125b transfection and putative targets of
miR-125b. Among them, we validated erythropoietin (EPO) and its receptor (EPOR) - frequently overexpressed in
breast cancer - as true targets of miR-125b. Moreover, we explored possible correlations with clinical variables and
we found a down-regulation of miR-125b in metastatic breast cancers and a significant positive correlation
between EPOR and ERBB2/HER2 levels, that are both targets of miR-125b and function as competing endogenous
RNAs (ceRNAs).
Conclusions: Taken together our results show a mechanism for EPO/EPOR and ERBB2 co-regulation in breast
cancer and confirm the importance of miR-125b in controlling clinically-relevant cancer features.
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MicroRNA (miRNA) expression deregulation in human
breast cancer was one of the first to be described world-
wide [1]. Among the most down-regulated miRNAs in
breast cancer compared to normal mammary tissue
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reproduction in any medium, provided the orpossible role for this miRNA as a tumor suppressor
gene. Indeed, its expression was found to be reduced or
completely lost in a variety of solid cancers including
lung [2,3], hepatic [4], thyroid [5], ovarian [6], cervical
[7] cancer, melanoma [8] and neuroblastoma [9] with
the exception of gastric [10] and pancreatic [11] cancers
in which it is up-regulated. A germline mutation in hsa-
miR-125a locus, that lead to reduced levels of miR-125a
(whose mature form is equal to miR-125b) has been de-
scribed in breast cancer patients [12].l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in malignant transformation emerged, with the identi-
fication of the oncogenic properties of miR-125b over-
expression in hematological malignancies [13-16]. The
overexpression of miR-125b in hematological neoplasia
is often due to translocations involving hsa-miR-125b-1
locus on chromosome 11q24: t(2;11) in myelodysplastic
syndrome and t(11;14) in acute lymphoblastic leukemia.
It seems therefore evident that miR-125b is an intriguing
miRNA with multiple functions as a regulator of cell pro-
liferation, differentiation and apoptosis that strictly depends
on the cellular context. Among the most relevant targets
in solid tumors there are the anti-apoptotic and pro-
proliferative proteins Bcl-2 [17], c-jun [8], c-raf [18], p53
[19], ERBB2 [20], ERBB3 [20], MUC1 [21], PIK3CD [22].
In breast cancer, miR-125b down-regulation is an early
event in cancer progression [23] and it is partially due to
its epigenetic regulation through promoter methylation
[24]. A reduced expression of this miRNA in people that
carry a mutation in ATM gene has been described [25].
Reduced levels of miR-125b have been linked to an in-
creased metastatic capability of breast cancer cells [24]
and to an increase in cell motility in vitro [26]. More-
over, a single nucleotide polymorphism in MRE
(miRNA response element) for miR-125b of BMPR1B
gene has been linked to the risk of developing breast
cancer [27].
In this study, we describe erythropoietin (EPO) and
erythropoietin receptor (EPOR) as novel targets of miR-
125b and we tested the hypothesis of an association be-
tween miRNA/targets expression and clinical outcomes
in breast cancer. Moreover, we discovered a cross-talk
between EPOR and ERBB2/HER2 based on their acting
as decoys for miR-125b.
Results
Identification of miR-125b target genes in MCF7 cell line
and their functional annotation
To identify possible targets of human miR-125b, we
transfected MCF7 breast cancer cell line with a miR-
125b mimic oligonucleotide (Ambion) or a negative
control oligonucleotide (#2, Ambion) and we collected
total RNA at 24 and 48 hours after transfection. Global
gene expression changes were examined using microarray
technology (Agilent Whole Human Genome microarray).
We applied Sylamer algorithm [28], that searches for
enriched sequences in 3′UTR of genes, to the list of genes
down-modulated by miR-125b both at 24 and 48 hours
after transfection. As expected, miR-125b seed sequence
(7- 8-mer) was significantly enriched in down-regulated
transcripts (Additional file 1: Figure S1). We found a list
of 315 genes (Additional file 2: Table S1) whose 3′UTR
contains at least 1 region complementary to the seed se-
quence of miR-125b (7-mers (C)TCAGGG(A) and 8-merCTCAGGGA) and whose expression is reduced after
transfection, thereby supporting a direct role of the
miRNA in causing mRNA down-regulation.
We analyzed the list of genes down-regulated after
miR-125b transfection and containing a potential
miRNA response element (MRE) with Metacore (Gen-
eGO) software and we found the significantly enriched
pathways (Table 1). Among them, there are two path-
ways concerning Erythopoietin (EPO) signaling and
the Metacore network analysis revealed that EPO sig-
naling is deeply influenced by miRNA transfection
(Figure 1). Indeed, both EPO and EPzOR (Erythopoietin
receptor) are putative targets of miR-125b (Additional
file 3: Figure S2) and their downregulation after miR-
125b transfection was validated by quantitative RT-PCR
(RT-qPCR), both at 24 and 48 hours (Additional file 4:
Figure S3).EPO and EPOR are target of miR-125b
Transfection experiments were performed in MCF7 and
HEK-293 cell lines to validate EPO and EPOR as targets
of miR-125b. EPO and EPOR 3′UTRs were cloned
downstream Renilla luciferase gene in psiCHECK-2 re-
porter vector. This vector contains also Firefly luciferase
gene that can be used as a reference in Dual-Luciferase
Reporter Assay (Promega). These vectors were trans-
fected in two different cell lines together with a vector
expressing miR-125b (pIRESneo2- miR125b), while the
empty pIRESneo2 vector, pIRES-neo2 vector expressing
miR-145 (that does not target EPO/EPOR 3′UTRs) and
the mutated version of psiCHECK-2 + 3′UTR plasmids
were used as negative controls. The luciferase activity of
the constructs containing EPO and EPOR-3′UTR was
suppressed of ~30% (p < .05) following ectopic expres-
sion of miR-125b (Figure 2) demonstrating that EPO/
EPOR expression is under the control of miR-125b.miR-125b and EPO/EPOR expression is inversely
correlated in breast cancer
We validated the opposite modulation of miR-125b, EPO
and EPOR by RT-qPCR in a cohort of 42 breast cancer pa-
tients and 13 normal samples collected at the University
of Ferrara (Figure 3A-C). We found a significant down-
regulation of miR-125b and an up-regulation of EPO and
EPOR genes (p = 0.0003, 0.03 and 0.002, respectively; un-
paired t-test with Welch’s correction). Likewise, a signifi-
cant inverse correlation between miR-125b and EPO (p =
0.0037) and EPOR (p = 0.03) genes was found (Spearman
correlation, r = −039; -0.31, Figure 3D). These observa-
tions confirm the role of miR-125b in controlling the up-
regulation of Erythropoietin and Erythropoietin receptor
in breast cancer.
Table 1 Pathways significantly enriched in the list of genes down-regulated by miR-125b and with a MRE in 3'UTR
(source: GeneGO Metacore)
# Maps pValue Ratio
1 Immune response_CD28 signaling 2.304E-04 5 54
2 Development_EPO-induced PI3K/AKT pathway and Ca(2+) influx 9.912E-04 4 43
3 Neurophysiological process_Melatonin signaling 9.912E-04 4 43
4 Development_A2A receptor signaling 9.912E-04 4 43
5 Development_EPO-induced MAPK pathway 1.178E-03 4 45
6 Development_WNT5A signaling 1.280E-03 4 46
7 Neurophysiological process_NMDA-dependent postsynaptic long-term potentiation in CA1 hippocampal neurons 1.417E-03 5 80
8 Nicotine signaling in dopaminergic neurons, Pt. 1 - cell body 1.502E-03 4 48
9 Development_A2B receptor: action via G-protein alpha s 1.750E-03 4 50
10 Signal transduction_PKA signaling 1.884E-03 4 51
11 Immune response_HSP60 and HSP70/ TLR signaling pathway 2.329E-03 4 54
12 Cell adhesion_Gap junctions 3.608E-03 3 30
13 Development_EGFR signaling pathway 4.086E-03 4 63
14 Oxidative stress_Role of ASK1 under oxidative stress 5.161E-03 3 34
15 Reproduction_GnRH signaling 6.576E-03 4 72
16 Development_Mu-type opioid receptor signaling 7.062E-03 3 38
17 Signal transduction_cAMP signaling 7.062E-03 3 38
18 Transcription_P53 signaling pathway 7.594E-03 3 39
19 Development_PACAP signaling in neural cells 7.594E-03 3 39
20 Apoptosis and survival_Lymphotoxin-beta receptor signaling 9.328E-03 3 42
21 Nicotine signaling in dopaminergic neurons, Pt. 2 - axon terminal 9.953E-03 3 43
22 Development_S1P1 signaling pathway 1.060E-02 3 44
23 Neurophysiological process_Glutamate regulation of Dopamine D1A receptor signaling 1.128E-02 3 45
24 Transcription_Androgen Receptor nuclear signaling 1.128E-02 3 45
25 Development_Thrombopoietin-regulated cell processes 1.128E-02 3 45
26 Development_GDNF family signaling 1.197E-02 3 46
27 Neurophysiological process_Dopamine D2 receptor signaling in CNS 1.269E-02 3 47
28 Development_TGF-beta-dependent induction of EMT via MAPK 1.269E-02 3 47
29 Development_HGF signaling pathway 1.269E-02 3 47
30 Immune response_Histamine H1 receptor signaling in immune response 1.344E-02 3 48
31 Immune response_Lectin induced complement pathway 1.421E-02 3 49
32 Development_A3 receptor signaling 1.421E-02 3 49
33 Immune response_Histamine signaling in dendritic cells 1.501E-02 3 50
34 Mucin expression in CF via TLRs, EGFR signaling pathways 1.501E-02 3 50
35 Immune response_NFAT in immune response 1.583E-02 3 51
36 Development_IGF-1 receptor signaling 1.667E-02 3 52
37 Signal transduction_Activation of PKC via G-Protein coupled receptor 1.667E-02 3 52
38 Cell adhesion_ECM remodeling 1.667E-02 3 52
39 Immune response_Classical complement pathway 1.667E-02 3 52
40 Development_Endothelin-1/EDNRA signaling 1.754E-02 3 53
41 Membrane-bound ESR1: interaction with G-proteins signaling 1.844E-02 3 54
42 Development_FGFR signaling pathway 1.844E-02 3 54
43 Immune response_Fc epsilon RI pathway 1.936E-02 3 55
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Table 1 Pathways significantly enriched in the list of genes down-regulated by miR-125b and with a MRE in 3'UTR
(source: GeneGO Metacore) (Continued)
44 Regulation of lipid metabolism_Insulin regulation of glycogen metabolism 2.030E-02 3 56
45 Cytoskeleton remodeling_FAK signaling 2.127E-02 3 57
46 Immune response_Immunological synapse formation 2.329E-02 3 59
47 Development_EGFR signaling via PIP3 2.351E-02 2 23
48 Development_Thyroliberin signaling 2.540E-02 3 61
49 Development_Gastrin in cell growth and proliferation 2.650E-02 3 62
50 G-protein signaling_K-RAS regulation pathway 2.750E-02 2 25
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metastatic potential and ERBB2 expression
To evaluate the significance of miR-125b, EPO and EPOR
expression in breast cancer, we examined their expression
levels in breast cancer patients, grouped according to the
following clinical-pathological variables: metastatic recur-
rence, p53 mutation, grade, stage, lymphnode invasion,
proliferative index, estrogen and progesterone receptors
positivity, ERBB2 overexpression. We found a significant
down-regulation of miR-125b levels in metastatic breast
cancers (Figure 4A) compared to not metastatic tumors
(p = 0.014, two-tailed Mann Whitney test). A reduced ex-
pression of miR-125b can be observed also in locally re-
current breast cancers, although only four samples were
available. EPO and EPOR levels were only slightly in-
creased in metastatic cancers without reaching signifi-
cance (data not shown).
ERBB2 (HER2) gene is a validated target of miR-125b
[20]. To confirm the regulation of ERBB2 by miR-125bFigure 1 Network analysis of genes modulated by miR-125b and puta
down-modulated after miR-125b transfection in MCF7 and containing a MR
EPO/EPOR signaling and involving several genes that are targeted by miR-1we examined the miRNA levels in breast cancers
strongly positive (positive cells > 50%) intermediately
positive (positive cells = 20-50%) and weakly positive or
negative (positive cells < 20%) for ERBB2 (Figure 4B). As
expected, miR-125b expression is significantly reduced in
strongly positive breast cancer (p = 0.04, two-tailed Mann
Whitney test). A significant inverse correlation was found
between miR-125b expression levels and ERBB2 protein
levels as well (Spearman correlation, r = −031; p = 0.04;
Figure 4C).
Since an extensive co-expression of ERBB2 and EPOR
has been described in breast cancer [29] and ERBB2 pro-
tein levels correlates with that of ERBB2 mRNA [30,31],
we evaluated the relationship between ERBB2 and EPOR
using gene expression data from 69 breast cancers with
low and intermediate levels of ERBB2 (data from propri-
etary microarray experiments, average or two probes for
each gene). Normalized expression data are available
in Additional file 5: Table S2. We found a significanttive targets of miR-125b. Network analysis, performed on genes
E in their 3′UTR, revealed two enriched network of genes relying on
25b (red circles).
Figure 2 EPO and EPOR are targets of miR-125b. Luciferase
reporter assays was performed with psiCHECK2 reporter vector after
placing Renilla luciferase under the control of the EPO/EPOR 3′UTR.
A not-targeting miRNA (miR-145), the empty pIRESneo2 vector and
the mutated version of psiCHECK2 vectors were used as controls.
The Renilla luciferase values were normalized for transfection with
Firefly luciferase activity and data are presented relative to the
vector control. The mean ± s.d. of three independent experiments in
two different cell lines is shown. *P <0.05.
Figure 3 Relative expression of miR-125b, EPO and EPOR in human b
miR-125b (C) was measured in 42 breast cancers and 13 normal breasts by
and genes respectively. 2-deltaCq method was used for normalized relative
between miR-125b and EPO and EPOR expression (P < .05 for both genes)
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sion levels (Spearman correlation, r = 0.54; two-tailed
p-value < 0.0001; Figure 4D). This result confirms the
data obtained from qPCR and IHC data that were previ-
ously described.
No significant association was found between miRNA/
gene expression levels and grade, stage, lymphnode inva-
sion, proliferative index, estrogen and progesterone re-
ceptors positivity.
EPOR and ERBB2 act as decoys for miR-125b
We hypothesized that ERBB2 and EPOR could act as
competing endogenous RNAs (ceRNAs), influencing their
respective levels using miR-125b response elements
present in their 3′ UTR. Since ERBB2 is frequently ampli-
fied or overexpressed in breast cancer [32], we used its 3′
UTR as a driver for EPOR levels through miR-125b decoy.
We selected two breast cancer cell lines (MDA-MB-453
and MDA-MB-157) characterized by low-intermediate
levels of endogenous ERBB2 (Additional file 6: Figure S4),
moderate-high EPOR expression [29] and low levels of en-
dogenous miR-125b (if compared to normal breast, data
not shown). We transfected both cell lines with pIRES-
ERBB2-3UTR plasmid that express ERBB2 3′UTR. We
used the empty plasmid as well as not-transfected cells
as controls. As represented in Figure 5, we observed areast cancer. The expression levels of EPO (A), EPOR (B) and
RT-qPCR. RNU6 and 18S were used as reference genes for miRNA
expression calculation. D) A statistically significant inverse correlation
was observed by using two-tailed Spearman’s test (log2 data).
Figure 4 Correlation of miR-125b and EPOR with metastasis and ERBB2. A) Expression of miR-125b (normalized on RNU6 and log2
transformed) in not metastatic (NM), locally recurrent (local) and metastatic (M) breast cancer, detected by RT-qPCR. A significant
two-tailed Mann Whitney test) down-regulation in metastatic BC can be observed. B) MiR-125b levels are significantly (p = 0.048, two-tailed
Mann Whitney test) down-regulated in ERBB2 strongly positive breast cancers (IHC positive cells > 50%) C) and display an inverse correlation
(Spearman r = 0.31, p = 0.04). D) Microarray data from 69 breast cancer without HER-2 amplification shows a highly concordant expression
(Spearman r = 0.54, p < 0.0001) of ERBB2/HER2 and EPOR levels.
Figure 5 ERBB2 3′UTR acts as a decoy for miR-125b. MDA-MD-453
and MDA-MB-157 (HER2+, EPOR+, miR-125b+) breast cancer cell lines
were transfected with pIRES-ERBB2-3’UTR vector and show increased
EPOR mRNA levels at 24 hours. Data were obtained from RT-qPCR
experiments performed in triplicate. 18S was used as reference gene.
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t-test) 24 hours after the transfection in both cell lines,
using RT-qPCR assay.
Discussion
Among the genes modulated after miR-125b transfection
and putative targets of the same miRNA, we focused our
attention on erythropoietin and its receptor. Erythropoi-
etin (EPO) has long been known as the cytokine that
regulates differentiation and survival of erythroid cells.
Recombinant human EPO (rHuEPO) has been used in
cancer patients for the treatment of chemotherapy-
induced anemia for two decades. However, recent stud-
ies revealed a more pleiotropic role for this cytokine and
several clinical trial reported an increase mortality in
cancer patients treated with erythropoiesis stimulating
agents (ESAs) compared to control groups [33].
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ceptor family and the binding with EPO ligand activates
many important pathways of the cell, such as JAK2/
STAT5, MAPK(ERK) and PI3K/AKT. EPO receptor is
expressed in a variety of non-hematopoietic human tissues
in which the EPO-EPOR signaling works to increase sur-
vival and to protect cells from injury [34]. In 2001, Acs
and coworkers first described an increased expression of
EPO-EPOR in breast cancer samples and cell lines, hy-
pothesizing a paracrine loop able to sustain cell prolifera-
tion [35]. Now, we know that EPO-EPOR signaling is
active in a variety of solid tumors [33], that EPO-EPOR
expression is particularly increased in hypoxic regions [36]
and can influence cancer resistance to pharmacological
treatments [29,37]. Specifically, it has been demonstrated
that EPOR activation is able to antagonize trastuzumab
therapeutic effect in vitro, thanks to the activation of a
proliferative signaling pathway overlapping with ERBB2
pathway [29] and that EPOR-positive breast cancer pa-
tients display a reduced response to tamoxifen [37].
In this work, we confirmed the down-regulation of
miR-125b and the up-regulation of EPO and EPOR in a
large panel of breast cancers. Moreover, we describe one
of the mechanisms that regulate EPO-EPOR expression
in breast cancer that is miRNA-dependent. Indeed, both
EPO and EPOR 3′UTRs have at least one target sequence
for miR-125b that responded to a miR-125b mimic trans-
fection in the context of breast cancer cells. Therefore,
we speculated that the described overexpression of EPO-
EPOR in several types of carcinoma could be at least in
part due to the concomitant loss of miR-125b.
In this study we further explored the correlation between
miR-125b, EPO, EPOR and clinical-pathological variables.
We found that miR-125b levels are reduced in metastatic
breast cancer, that is congruent with its role as a tumor
suppressor miRNA in this cancer type and with published
data [18,24,38]. We found also a reduced expression of
miR-125b in breast cancers strongly positive for ERBB2,
that is coherent with its being a target of the miRNA. Since
EPOR and ERBB2 are both target of the tumor suppressor
miR-125b, we searched for a correlation between EPOR
and ERBB2 expression in an independent cohort of breast
cancers. We found a positive correlation between the levels
of the two receptors, suggesting the existence of mecha-
nisms of co-regulation and possibly functional cooperation,
especially in breast cancers where ERBB2/HER2 increased
levels cannot alone sustain/explain the malignant behavior.
Indeed, both genes are regulated by miR-125b and are able
to activate the same molecular pathways.
By examining the ability of ERBB2 3′UTR to function
as a decoy of miR-125b, we were indeed able to induce
an increase in EPOR levels, probably by reducing the
amount of “free” cellular miR-125b, thereby revealing a
mechanism for their positive correlation. Notably, it hasalso been recently demonstrated that miR-125b can target
PIK3CD [22], a key mediator of both EPOR and ERBB2
downstream pathways. The reduced levels of miR-125b in
breast cancer cells suggests that both ERBB2 and EPOR
could become up-regulated and actively cooperate to in-
crease cell proliferation and reduce the apoptotic rate in
cancer cells. The active role of these receptors in promot-
ing breast cancers needs to be further studied, to better
understand their role and possible cooperation in sustain-
ing the growth of breast cancer cells. Indeed, a recent re-
port indicated that HER2 negative tumors may still benefit
of anti HER2 therapies [39].
Conclusions
In conclusion, we demonstrated that the tumor-
suppressive miR-125b is able to modulate erythropoi-
etin/ erythropoietin receptor axis in breast cancer and
display a negative correlation with its metastatic poten-
tial. The erythropoietin receptor has a positive correl-
ation with the epidermal growth factor receptor b2, that
is explained by their acting as decoy molecules for miR-
125b. Finally, our study indicates that a special attention
should be given to miR-125b whose role as tumor-
suppressor in several solid cancers is becoming strong.
miR-125b is definitely a significant cancer-associated
miRNA and the comprehension of its mechanism of ac-
tion in specific cellular contexts is important to evaluate




Breast cancer and normal breast tissues were anonym-
ously collected at the University of Ferrara (Italy) and ex-
tensively characterized for clinical and bio-pathologic
status by two expert pathologists (P.Q. and M.P.). Clinico-
pathological information concerning metastasis develop-
ment, ERBB2/HER2 expression, p53 mutation, grade,
stage, lymphnode invasion, proliferative index, estrogen
and progesterone receptors positivity was available for all
tumor samples and determined as previously described
[1]. Total RNA isolation was performed with Trizol (Invi-
trogen) according to the manufacturer’s instructions.
Cell lines and transfection
MDA-MB-453, MDA-MB-157, MCF7 and HEK-293 cell
lines were obtained from the ATCC and were cultured
with ISCOVE’s Modified Dulbecco’s Medium (Lonza
BioWhittaker) with 10% fetal bovine serum (FBS) and
gentamicin. For microarray experiments, MCF7 cell line
was transfected with 100 nM of miR-125b (Ambion) or
Negative Control#2 (Ambion); total RNA was extracted at
24hs and 48 hs after transfection by adding Trizol Reagent
(Invitrogen) according to manufacturer’s procedure. The
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media. Transfection of miRNAs was carried out using
Lipofectamine 2000 (Life Technologies) in accordance
with manufacturer’s procedure.
Plasmids
The human EPO and EPOR 3′-UTR target sites were
amplified by PCR using the following primers: EPO-
3UTR_F: 5′- ATCTCGAGCTCCCTCACCAACATTGC
TT-3′; EPO-3UTR_R: 5′- ATGTTTAAACGTCTTCAT
GGTTCCCACCAC-3′; EPOR-3UTR_F: 5′- ATCTCG
AGCCAGCTATGTGGCTTGCTCT-3′; EPOR-3UTR_R:
5′- ATGTTTAAACACTGCAAGGTTGTGGTTTCC-3′
and cloned downstream of the Renilla luciferase gene in
psiCHECK-2 vector (Promega). Mutated 3′UTRs, through
the deletion of the miR-125b seeds inside EPO and EPOR
3′UTRs, were generated using gBlocks Gene Fragments
(IDT). These vectors - psiCHECK2-EPO, psiCHECK2-
EPOR and their mutated versions - were used for transfec-
tion into MCF7 and HEK-293 cells. Vector expressing
miR-125b and miR-145 (used as negative control) were
obtained after cloning miR-125b and miR-145 genomic se-
quences in pIRESneo2 expression vector (Clontech). The
level of miR-125b expression in transfected cells was
assayed by RT-qPCR (TaqMan MicroRNA Assays, Life
Technologies) 24hs and 48 hs after transfection (data not
shown). The 3′-UTR of ERBB2 was amplified by PCR
from the cDNA of T47D and SK-BR3 cell lines (HER2
positive) and cloned into XbaI and EcoRI sites of pIRES-
neo2 expression plasmid.
Luciferase assay
MCF7 and HEK-293 cell lines were seeded in 24-well
plates at a cellular concentration of 40,000 and 100,000
cells/well respectively. Cells were transfected with 400
ngs of psiCHECK2-EPO or equimolar amounts of
psiCHECK2-EPOR or mutant control vectors together
with equimolar amounts of pIRESneo2-miR125b or
pIRESneo2-control (miR-145). Transfection was per-
formed using Lipofectamine 2000 and OPTI-MEM I Re-
duced Serum Medium (GIBCO). Twenty-four hours
after transfection Firefly and Renilla luciferase activity
were measured using the Dual-Luciferase Reporter
Assay (Promega). Each transfection was repeated in
triplicate.
Sponge experiment
MDA-MB-453 (7x105/well) and MDA-MB-157 (2x105/
well) were seeded in 6-well plates in antibiotic-free
media. The following day, they were transfected with
2.5 μg of pIRESneo2 or pIRES-ERBB2-3UTR using
Lipofectamine LTX (Life Technologies) and OPTI-MEM I
Reduced Serum Medium according to the manufacturer’s
recommendations. 24 hours later, cells were collectedusing Trizol Reagent for RNA extraction. The primers




Mature miRNAs expression was evaluated by Taqman
miRNA assays (Applied Biosystem) specific for miR-125b
(miR-125b-5b in miRBase release 19) and RNU6B as refer-
ence gene according to the manufacturer’s protocol.
Briefly, 5 ng of total RNA was reverse transcribed using
the specific looped primer; reverse transcription quantita-
tive PCR was conducted using the standard Taqman
miRNA assay protocol on a Biorad-Chromo4 thermal cy-
cler. EPO (assay ID Hs01071097_m1) and EPOR (assay ID
Hs00959427_m1) gene expression was assessed by RT-
qPCR using Taqman gene expression assays (Applied Bio-
system) according to manufacturer’s protocol. 18S was
used as reference gene and its expression was assessed
using the following primers F: 5′- CTGCCCTATCAACT
TTCGATGGTAG-3′; R: 5′- CCGTTTCTCAGGCTCCC
TCTC-3′ and KAPA SYBR FAST master mix (Kapa Bio-
systems). Each sample was analyzed in triplicate. The level
of each miRNA/gene was measured using Cq (threshold
cycle). The amount of target, normalized on reference
gene, was calculated using 2-ΔCq (Comparative Cq)
method. Graphs and statistical analyses were performed
using GraphPad Prism 5 software.Microarray and data analysis
Four samples derived from MCF7 transfection with miR-
125b at 24 and 48 hrs were used for microarray analysis.
Global gene expression was detected using Agilent Whole
Human Genome microarray (#G4112F, Agilent Technolo-
gies), which represent 41,000 unique human transcripts.
About 500 ngs of total RNA were employed in each ex-
periment. RNA labeling and hybridization were performed
in accordance to manufacturer’s indications. Agilent scan-
ner and the Feature Extraction software v.10.5 (Agilent
Technologies) were used to obtain the microarray raw-
data. Raw data have been submitted to ArrayExpress with
the following accession number: E-MTAB-1604. Micro-
array results were analysed using the GeneSpring GX 12
software (Agilent Technologies, Palo Alto, CA). Data
transformation was applied to set all negative raw values
at 1.0, followed by a normalization on 75th percentile. A
filter on low gene expression was used to keep only the
probes expressed in at least one sample. Genes were or-
dered from the most down-regulated at 24 and 48hrs
compared to controls to the most up-regulated and used
for sylamer analysis.
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Functional Ontology Enrichment analysis and Pathway
map visualization was performed using MetaCore path-
way analysis by GeneGo (GeneGo Inc.).
Sylamer analysis
Sylamer analysis was performed through the web-interface
Sylarray (http://www.ebi.ac.uk/enright-srv/sylarray) to de-
tect miR-125b target sequence in 3′ untranslated regions
(3′UTR) from a ranked gene list, sorted from downregu-
lated to upregulated in MCF7 +miR-125b at 24 and 48
hours compared to negative controls, as described in [28].
A significant enrichment and/or depletion of 7–8 nts se-
quences complementary to the miRNAs seeds in the 3′
UTR of ordered mRNAs was calculated using hypergeo-
metric statistic.
Statistical analyses
Statistical analyses were performed using GraphPad
Prism 5 software. Two-tailed Mann Whitney and un-
paired t-test, with or without Welch’s correction, were
used for statistical comparisons as specified in the text,
according to data distribution. Correlations were calcu-
lated using log2 transformed data and Spearman r cor-
relation (two-tailed p-value).
Additional files
Additional file 1: Figure S1. miR-125b seed is enriched in
down-regulated probes. Sylamer analysis of down-regulated mRNAs
revealed a significant enrichment in genes whose 3′UTR contain a
miR-125b response element (7-mers and 8-mers seed sequences) and
are down-regulated after miR-125b transfection (ordered from the most
down-regulated to the less).
Additional file 2: Table S1. List of 315 genes down-regulated after
miR-125b transfection and potential targets of the miRNA.
Additional file 3: Figure S2. EPO/EPOR::miR-125b binding sites. Binding
sites of miR-125b in EPO and EPOR 3′UTR detected by DIANA MicroT
tools (http://diana.cslab.ece.ntua.gr/microT/).
Additional file 4: Figure S3. Down-regulation of EPO and EPOR upon
the transfection of miR-125b.The expression levels of EPO (A), EPOR
(B) was measured in MCF7 breast cancer cell line after 24 and 48 hours
from transfection of miR-125b, by RT-qPCR. 18S was used as reference
gene and 2-deltaCq method was used for relative expression calculation.
The extent of reduction is referred to MCF7 transfected with the
scramble (P < .001 for both time points). Each experiment was performed
in triplicate.
Additional file 5: Table S2. Normalized gene expression data of EPOR
and ERBB2 probes, spotted on Agilent microarray, in 69 breast cancers.
Additional file 6: Figure S4. Expression of ERBB2 in breast cancer cell
lines. MDA-MB-157 and MDA-MB-453 show null or moderate levels of
ERBB2 expression, respectively, if compared to MDA-MB-231 (triple
negative cell line) and to SK-BR3 (HER2/ERBB2-amplified cell line). The
normalized expression was calculated by RT-qPCR using 18S as reference
gene; 2-deltaCq method was used for relative expression calculation.
Each experiment was performed in triplicate.
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